A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 30,600 shares of AGIO stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,600
Previous 11,200 173.21%
Holding current value
$1.37 Million
Previous $249,000 259.04%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$21.32 - $34.81 $1.54 Million - $2.52 Million
-72,351 Reduced 6.73%
1,002,461 $29.3 Million
Q4 2023

Feb 14, 2024

BUY
$19.97 - $24.53 $13.1 Million - $16.1 Million
658,194 Added 157.99%
1,074,812 $23.9 Million
Q3 2023

Nov 14, 2023

BUY
$24.36 - $28.18 $5.88 Million - $6.8 Million
241,427 Added 137.81%
416,618 $10.3 Million
Q2 2023

Aug 14, 2023

SELL
$21.38 - $29.19 $2.31 Million - $3.15 Million
-107,963 Reduced 38.13%
175,191 $4.96 Million
Q1 2023

May 15, 2023

BUY
$21.74 - $30.93 $1.39 Million - $1.98 Million
64,137 Added 29.28%
283,154 $6.5 Million
Q4 2022

Feb 14, 2023

SELL
$24.81 - $31.52 $760,054 - $965,615
-30,635 Reduced 12.27%
219,017 $6.15 Million
Q3 2022

Nov 14, 2022

SELL
$19.51 - $34.14 $1.64 Million - $2.87 Million
-83,929 Reduced 25.16%
249,652 $7.06 Million
Q2 2022

Aug 15, 2022

BUY
$17.06 - $31.42 $5.15 Million - $9.48 Million
301,818 Added 950.22%
333,581 $7.4 Million
Q1 2022

May 16, 2022

BUY
$26.68 - $34.81 $307,727 - $401,498
11,534 Added 57.02%
31,763 $925,000
Q4 2021

Feb 14, 2022

SELL
$29.58 - $49.78 $2.31 Million - $3.9 Million
-78,253 Reduced 79.46%
20,229 $664,000
Q3 2021

Nov 15, 2021

SELL
$41.92 - $58.18 $3.41 Million - $4.74 Million
-81,391 Reduced 45.25%
98,482 $4.55 Million
Q1 2021

May 17, 2021

BUY
$44.23 - $57.5 $7.03 Million - $9.15 Million
159,051 Added 763.86%
179,873 $9.29 Million
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $6.03 Million - $8.45 Million
-181,609 Reduced 89.71%
20,822 $902,000
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $3.35 Million - $5.54 Million
99,032 Added 95.78%
202,431 $7.09 Million
Q2 2020

Aug 14, 2020

SELL
$34.45 - $53.48 $13.1 Million - $20.4 Million
-381,542 Reduced 78.68%
103,399 $5.53 Million
Q1 2020

May 15, 2020

BUY
$31.52 - $53.81 $7.58 Million - $12.9 Million
240,568 Added 98.44%
484,941 $17.2 Million
Q4 2019

Feb 14, 2020

SELL
$30.08 - $50.59 $3.35 Million - $5.64 Million
-111,529 Reduced 31.34%
244,373 $11.7 Million
Q3 2019

Nov 14, 2019

SELL
$32.4 - $49.58 $8.92 Million - $13.6 Million
-275,156 Reduced 43.6%
355,902 $11.5 Million
Q2 2019

Aug 14, 2019

BUY
$46.17 - $68.1 $9.54 Million - $14.1 Million
206,570 Added 48.66%
631,058 $31.5 Million
Q1 2019

May 15, 2019

BUY
$45.92 - $67.67 $6.58 Million - $9.69 Million
143,253 Added 50.94%
424,488 $0
Q4 2018

Feb 14, 2019

BUY
$42.73 - $76.53 $4.89 Million - $8.75 Million
114,345 Added 68.52%
281,235 $13 Million
Q3 2018

Nov 13, 2018

BUY
$71.67 - $91.95 $11.7 Million - $15 Million
163,389 Added 4666.92%
166,890 $0
Q2 2018

Aug 10, 2018

SELL
$73.22 - $99.55 $1.09 Million - $1.48 Million
-14,854 Reduced 80.93%
3,501 $0
Q1 2018

May 11, 2018

SELL
$59.83 - $86.53 $4.37 Million - $6.33 Million
-73,115 Reduced 79.93%
18,355 $1.5 Million
Q4 2017

Feb 09, 2018

BUY
$52.12 - $72.33 $4.77 Million - $6.62 Million
91,470
91,470 $5.23 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.45B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.